Custom Search

News

Sunday 01 December 2002

Rituximab for immune hemolytic anemia following T- and B-Cell-depleted hematopoietic stem cell transplantation.

By: Corti P, Bonanomi S, Vallinoto C, Balduzzi A, Uderzo C, Cazzaniga G, Gaipa G, Dassi M, Perseghin P, Rovelli A.

Acta Haematol 2003;109(1):43-5

The treatment of immune-mediated hemolytic anemia (IHA) complicating hematopoietic stem cell transplantation (HSCT) is often unsatisfactory. We report a case of IHA which occurred after T- and B-cell depleted unrelated donor HSCT carried out for mucopolysaccharidosis type I-H (Hurler syndrome) which was successfully treated with anti-CD20+ monoclonal antibody Copyright 2003 S. Karger AG, Basel

Use of this site is subject to the following terms of use